These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 16006204

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.
    Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D, McKinnon AD, Nesbitt SA, Horton MA, Seabra MC, Ebetino FH, Rogers MJ.
    J Biol Chem; 2001 Dec 21; 276(51):48213-22. PubMed ID: 11581260
    [Abstract] [Full Text] [Related]

  • 4. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
    Roelofs AJ, Hulley PA, Meijer A, Ebetino FH, Russell RG, Shipman CM.
    Int J Cancer; 2006 Sep 15; 119(6):1254-61. PubMed ID: 16619218
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
    Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP.
    J Bone Miner Res; 2006 May 15; 21(5):684-94. PubMed ID: 16734383
    [Abstract] [Full Text] [Related]

  • 6. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug 15; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
    McKenna CE, Kashemirov BA, Błazewska KM, Mallard-Favier I, Stewart CA, Rojas J, Lundy MW, Ebetino FH, Baron RA, Dunford JE, Kirsten ML, Seabra MC, Bala JL, Marma MS, Rogers MJ, Coxon FP.
    J Med Chem; 2010 May 13; 53(9):3454-64. PubMed ID: 20394422
    [Abstract] [Full Text] [Related]

  • 9. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G.
    Arch Biochem Biophys; 2000 Jan 01; 373(1):231-41. PubMed ID: 10620343
    [Abstract] [Full Text] [Related]

  • 10. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA, Rodan GA.
    Mini Rev Med Chem; 2004 Sep 01; 4(7):711-9. PubMed ID: 15379639
    [Abstract] [Full Text] [Related]

  • 11. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
    Thompson K, Dunford JE, Ebetino FH, Rogers MJ.
    Biochem Biophys Res Commun; 2002 Jan 18; 290(2):869-73. PubMed ID: 11785983
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 16. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
    Hughes A, Rogers MJ, Idris AI, Crockett JC.
    Calcif Tissue Int; 2007 Nov 15; 81(5):403-13. PubMed ID: 17982704
    [Abstract] [Full Text] [Related]

  • 17. Bisphosphonates: the first 40 years.
    Russell RG.
    Bone; 2011 Jul 15; 49(1):2-19. PubMed ID: 21555003
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates: mode of action and pharmacology.
    Russell RG.
    Pediatrics; 2007 Mar 15; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [Abstract] [Full Text] [Related]

  • 19. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
    Staal A, Frith JC, French MH, Swartz J, Güngör T, Harrity TW, Tamasi J, Rogers MJ, Feyen JH.
    J Bone Miner Res; 2003 Jan 15; 18(1):88-96. PubMed ID: 12510809
    [Abstract] [Full Text] [Related]

  • 20. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ.
    J Bone Miner Res; 1998 Apr 15; 13(4):581-9. PubMed ID: 9556058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.